117 related articles for article (PubMed ID: 19995707)
41. [K-ras mutation analysis in ovarian serous borderline and malignant tumors].
Ma L; Guo LN; Liang ZY; Ren XY; Wu SF
Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):714-8. PubMed ID: 17374253
[TBL] [Abstract][Full Text] [Related]
42. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
Singer G; Oldt R; Cohen Y; Wang BG; Sidransky D; Kurman RJ; Shih IeM
J Natl Cancer Inst; 2003 Mar; 95(6):484-6. PubMed ID: 12644542
[TBL] [Abstract][Full Text] [Related]
43. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2008 Apr; 27(2):151-60. PubMed ID: 18317228
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
45. The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.
Kuhn E; Ayhan A; Shih IeM; Seidman JD; Kurman RJ
Mod Pathol; 2014 Feb; 27(2):231-7. PubMed ID: 23887305
[TBL] [Abstract][Full Text] [Related]
46. Immunophenotypic analysis of ovarian endometrioid adenocarcinoma: correlation with KRAS mutation and the presence of endometriosis.
Stewart CJ; Walsh MD; Budgeon CA; Crook ML; Buchanan DB
Pathology; 2013 Oct; 45(6):559-66. PubMed ID: 24018808
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic inactivation of tumor suppressor SFRP2 and point mutation in KRAS proto-oncogene in fistula-associated mucinous type anal adenocarcinoma: report of two cases.
Sen M; Ozdemir O; Turan M; Arici S; Yildiz F; Koksal B; Goze F
Intern Med; 2010; 49(15):1637-40. PubMed ID: 20686305
[TBL] [Abstract][Full Text] [Related]
48. Molecular pathogenesis of borderline and invasive ovarian tumors.
Stanojevic Z; Djordjevic B; Pajovic SB; Zivanov-Curlis J; Najman S
J BUON; 2009; 14(1):7-18. PubMed ID: 19373941
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas.
Sasaki H; Yano M; Fujii Y
J Thorac Oncol; 2010 Oct; 5(10):1715-6. PubMed ID: 20871271
[No Abstract] [Full Text] [Related]
50. Mucinous tumours of the ovary.
Naik JD; Seligmann J; Perren TJ
J Clin Pathol; 2012 Jul; 65(7):580-4. PubMed ID: 22011449
[TBL] [Abstract][Full Text] [Related]
51. Lack of KRAS gene mutations in chronic myeloid leukemia in Iran.
Kooshyar MM; Ayatollahi H; Keramati MR; Sadeghian MH; Miri M; Sheikhi M
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6653-6. PubMed ID: 24377583
[TBL] [Abstract][Full Text] [Related]
52. Climbing RAS, the everest of oncogenes.
Russo M; Di Nicolantonio F; Bardelli A
Cancer Discov; 2014 Jan; 4(1):19-21. PubMed ID: 24402942
[TBL] [Abstract][Full Text] [Related]
53. Minireview: physiological and pathological actions of RAS in the ovary.
Fan HY; Richards JS
Mol Endocrinol; 2010 Feb; 24(2):286-98. PubMed ID: 19880654
[TBL] [Abstract][Full Text] [Related]
54. Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.
Quaye L; Song H; Ramus SJ; Gentry-Maharaj A; Høgdall E; DiCioccio RA; McGuire V; Wu AH; Van Den Berg DJ; Pike MC; Wozniak E; Doherty JA; Rossing MA; Ness RB; Moysich KB; Høgdall C; Blaakaer J; ; Easton DF; Ponder BA; Jacobs IJ; Menon U; Whittemore AS; Krüger-Kjaer S; Pearce CL; Pharoah PD; Gayther SA
Br J Cancer; 2009 Mar; 100(6):993-1001. PubMed ID: 19240718
[TBL] [Abstract][Full Text] [Related]
55. Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS.
Stelniec-Klotz I; Legewie S; Tchernitsa O; Witzel F; Klinger B; Sers C; Herzel H; Blüthgen N; Schäfer R
Mol Syst Biol; 2012; 8():601. PubMed ID: 22864383
[TBL] [Abstract][Full Text] [Related]
56. [Molecular genetic of ovarian cancer].
Yanaihara N; Okamoto A; Ochiai K; Tanaka T
Nihon Rinsho; 2012 Jun; 70 Suppl 4():475-9. PubMed ID: 23156293
[No Abstract] [Full Text] [Related]
57. Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a
Colombo I; Garg S; Danesh A; Bruce J; Shaw P; Tan Q; Quevedo R; Braunstein M; Oza AM; Pugh T; Lheureux S
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31836588
[TBL] [Abstract][Full Text] [Related]
58. Gene of the month: KRAS.
Chetty R; Govender D
J Clin Pathol; 2013 Jul; 66(7):548-50. PubMed ID: 23626007
[TBL] [Abstract][Full Text] [Related]
59. Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study.
Horsch M; Recktenwald CV; Schädler S; Hrabé de Angelis M; Seliger B; Beckers J
Br J Cancer; 2009 Feb; 100(4):656-62. PubMed ID: 19190631
[TBL] [Abstract][Full Text] [Related]
60. High Frequency of Codon 12 but not Codon 13 and 61 K-ras Gene Mutations in Invasive Ductal Carcinoma of Breast in a South Indian Population.
Sushma C; Prasad S; Devi R; Murthy S; Rao Ts; Naidu C
Asian Pac J Cancer Prev; 2015; 16(8):3505-8. PubMed ID: 25921169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
